Alessia Izzo, Rosa Costanzo, Lucia De Martino, Salvatore Di Napoli
{"title":"Does EFSA statement on Monacolin content of nutraceutical combinations impair their lipid lowering effect? The LopiGLIK experience.","authors":"Alessia Izzo, Rosa Costanzo, Lucia De Martino, Salvatore Di Napoli","doi":"10.1186/s40842-024-00204-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Monacolin-K, the active component of red yeast rice (RYR), reduces cholesterol by inhibiting HMG-CoA reductase. Following safety concerns, the European Food Safety Authority (EFSA) recommended limiting Monacolin-K intake to less than 3 mg/day due to adverse effects at higher doses.</p><p><strong>Case presentation: </strong>A study comparing Armolipid Plus<sup>®</sup> and LopiGLIK<sup>®</sup> found LopiGLIK<sup>®</sup> more effective in lowering LDL cholesterol, possibly due to slightly higher dosages of Berberine and Monacolin-K. Despite reducing Monacolin-K content to 2.99 mg following EFSA guidelines, LopiGLIK<sup>®</sup> maintained its cholesterol-lowering efficacy.</p><p><strong>Conclusions: </strong>Taken together, our results indicate that other ingredients, such as Morus alba, may contribute to LopiGLIK<sup>®</sup>'s enhanced effectiveness, challenging the notion that minor differences in Monacolin-K dosage account for the observed efficacy.</p>","PeriodicalId":56339,"journal":{"name":"Clinical Diabetes and Endocrinology","volume":"10 1","pages":"38"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Diabetes and Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40842-024-00204-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Monacolin-K, the active component of red yeast rice (RYR), reduces cholesterol by inhibiting HMG-CoA reductase. Following safety concerns, the European Food Safety Authority (EFSA) recommended limiting Monacolin-K intake to less than 3 mg/day due to adverse effects at higher doses.
Case presentation: A study comparing Armolipid Plus® and LopiGLIK® found LopiGLIK® more effective in lowering LDL cholesterol, possibly due to slightly higher dosages of Berberine and Monacolin-K. Despite reducing Monacolin-K content to 2.99 mg following EFSA guidelines, LopiGLIK® maintained its cholesterol-lowering efficacy.
Conclusions: Taken together, our results indicate that other ingredients, such as Morus alba, may contribute to LopiGLIK®'s enhanced effectiveness, challenging the notion that minor differences in Monacolin-K dosage account for the observed efficacy.
期刊介绍：
Clinical Diabetes and Endocrinology is an open access journal publishing within the field of diabetes and endocrine disease. The journal aims to provide a widely available resource for people working within the field of diabetes and endocrinology, in order to improve the care of people affected by these conditions. The audience includes, but is not limited to, physicians, researchers, nurses, nutritionists, pharmacists, podiatrists, psychologists, epidemiologists, exercise physiologists and health care researchers. Research articles include patient-based research (clinical trials, clinical studies, and others), translational research (translation of basic science to clinical practice, translation of clinical practice to policy and others), as well as epidemiology and health care research. Clinical articles include case reports, case seminars, consensus statements, clinical practice guidelines and evidence-based medicine. Only articles considered to contribute new knowledge to the field will be considered for publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
